Ectaprim

Quick links to important sections

Ectaprim

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ectaprim

What is Ectaprim?

Ectaprim is a combination antibacterial medication composed of two active ingredients: sulfamethoxazole and trimethoprim. It belongs to a class of drugs known as sulfonamides (or sulfa drugs) and folate antagonists. By combining these two agents, the medication achieves a synergistic effect that inhibits the growth of various types of bacteria.

Mechanism of Action

The two components of Ectaprim work by disrupting the production of dihydrofolic acid and tetrahydrofolic acid, which are essential forms of folic acid that bacteria need to synthesize nucleic acids and proteins.

  • Sulfamethoxazole interferes with the first step of this process by competing with para-aminobenzoic acid (PABA).
  • Trimethoprim blocks a subsequent step by inhibiting the enzyme dihydrofolate reductase.

Because human cells do not synthesize folic acid in the same manner as bacteria, the medication specifically targets the metabolic pathways of the infecting microorganisms.

Common Uses

Ectaprim is utilized to treat a wide range of bacterial infections. It is effective against both Gram-positive and Gram-negative bacteria, though it is not effective against viral infections such as the common cold or influenza. Common applications include:

  • Urinary Tract Infections (UTIs): Treatment of infections involving the bladder or kidneys.
  • Respiratory Infections: Management of bacterial bronchitis and certain types of pneumonia.
  • Gastrointestinal Infections: Treatment of conditions such as shigellosis or traveler's diarrhea.
  • Otitis Media: Use in pediatric or adult ear infections when caused by susceptible bacterial strains.

Forms and Availability

This medication is typically available in several formats to accommodate different patient needs, including oral tablets and liquid oral suspensions. The ratio of sulfamethoxazole to trimethoprim is standardized to ensure the optimal synergistic balance between the two components.

Regulatory References

  1. Sulphamethoxazole

What side effects are possible with Ectaprim?

Possible Side Effects and Safety Information

Safety data for Ectaprim (Co-trimoxazole) reflects a profile documented across several organ systems, consistent with classifications published by regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The potential adverse effects are categorized by their frequency and the body system affected.


Officially Documented Adverse Reactions and Frequency

System-Organ Class (SOC) Frequency Official Regulatory Listing
Metabolism and Nutrition Very Common Hyperkalaemia (increased blood potassium)
Gastrointestinal Disorders Common Nausea, Diarrhoea
Skin and Subcutaneous Tissue Common Rash

Other effects listed in official documents with a Very Rare frequency include serious blood disorders (e.g., Agranulocytosis, Aplastic Anaemia) and severe cutaneous reactions.


Serious Adverse Reactions and Safety Constraints

The medicine is associated with serious adverse reactions, including potentially fatal conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Regulatory documents note that the highest risk for these severe skin reactions is generally within the first weeks of treatment. Discontinuation is specified as required at the first appearance of any skin rash or sign of a serious adverse event.


Population-Specific Safety Considerations

Official labeling highlights specific safety constraints for certain patient groups. Older adults may have an increased susceptibility to serious side effects, including severe skin rash and hyperkalaemia, often linked to underlying organ impairment. The medicine is contraindicated in Infants under two months of age and in individuals with severe hepatic damage or severe renal insufficiency when function cannot be monitored. Patients with G6PD deficiency are at risk of haemolytic anaemia.

Overdose and Emergency Response

Overdose and when to Seek Help for Ectaprim (Co-trimoxazole)

This section describes the overdose manifestations and emergency actions documented in official regulatory sources for Ectaprim (Co-trimoxazole).


Documented Overdose Manifestations

Overdosage is classified by both acute and chronic effects. Acute overdose may present with symptoms including nausea, vomiting, confusion, and loss of appetite. Signs involving the urinary system, such as hematuria (blood in the urine) and crystalluria, are also documented. Chronic overdosage is associated with the anti-folate action of trimethoprim, potentially leading to megaloblastic anemia and other blood dyscrasias. Severe outcomes listed include hyperkalemia, circulatory shock, and fulminant hepatic necrosis.


Required Emergency Actions

Immediate medical attention must be sought upon suspicion of an overdose. Regulatory guidance mandates calling emergency services immediately if signs such as collapse, seizure, or trouble breathing are observed. Treatment should be discontinued, and urgent medical advice sought at the first sign of a severe skin rash. Overdose management is officially described as supportive, including the administration of activated charcoal and fluid management. To counteract severe trimethoprim toxicity, the specific intervention described is the use of folinic acid. Elderly patients and those with impaired renal function are noted to be more susceptible to serious effects.

Therapeutic Uses of Ectaprim

What Ectaprim treats: main uses and benefits

The primary therapeutic role of Ectaprim (Co-trimoxazole) is applied in addressing infections across key anatomical areas, contributing to symptomatic relief and is commonly used during phases when symptoms become more noticeable. This medication is commonly used across conditions presenting with symptoms of urinary tract infections, diarrhea associated with acute or episodic changes, Traveler's Diarrhea, pneumonia, and skin and soft tissue infections.

It helps address symptom clusters used when groups of symptoms appear suddenly or fluctuate, such as painful urination and gastrointestinal distress, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It is also considered relevant in clinical settings marked by heightened distress from severe bacterial diseases, including acute exacerbations of chronic bronchitis and infections associated with acute or disruptive episodes.

Ectaprim provides supportive relief against specific opportunistic pathogens, particularly for immunocompromised patient groups. This focused prophylactic use, such as for Pneumocystis Jirovecii Pneumonia (PJP) and Toxoplasmosis, assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Systemic Discomfort Ectaprim supports the easing of overall symptom load, relevant for managing symptoms that interfere with daily comfort, and supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ectaprim (Co-trimoxazole) — Official Regulatory Information

Category Regulatory Statement (Strictly Label-Based)
Populations for Whom Use is Allowed Adults and pediatric patients two months of age and older are eligible for use.
Populations for Whom Use is Contraindicated Patients with known hypersensitivity to trimethoprim or sulfonamides; individuals with severe hepatic damage or severe renal insufficiency (Creatinine Clearance < 15 mL/min); and those with documented megaloblastic anemia due to folate deficiency.

Age-Group and Reproductive Status

Status Regulatory Statement
Age-Related Eligibility Use is prohibited for infants younger than two months of age. Older adults are eligible, but use requires particular care and monitoring.
Pregnancy and Lactation The medicine is contraindicated for pregnant women at term and nursing mothers.

Eligibility-Related Restrictions

Official regulations require a 50% dose reduction for patients with impaired renal function (CrCl 15 to 30 mL/min). Caution is advised when treating patients with certain metabolic disorders, such as glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. These rules reflect the standardized regulatory classification that defines patient eligibility based solely on their physiological and clinical profile.

What should I know about interactions with other medicines?

The official regulatory profile for Ectaprim (Co-trimoxazole) defines several classes of interaction that require attention.

Co-administration with the anti-arrhythmic medicine Dofetilide is formally contraindicated across regulatory jurisdictions due to the documented risk of serious ventricular arrhythmias. Similarly, co-use with Clozapine is prohibited in some regions due to the documented risk of severe hematological toxicity.

A significant interaction mechanism involves the inhibition of metabolism, which increases the exposure of co-administered drugs. This leads to prolonged half-life and elevated plasma levels for medicines such as the anti-epileptic Phenytoin and the anti-coagulant Warfarin. For Warfarin, Ectaprim is known to potentiate its activity. Furthermore, Ectaprim inhibits the renal tubular secretion of compounds like Procainamide and Amantadine, and increases the exposure of Digoxin, a risk particularly noted in elderly patients.

A critical pharmacodynamic interaction exists with agents that affect potassium balance, such as ACE Inhibitors and Potassium-Sparing Diuretics. Co-use with these medicines carries a documented increased risk of hyperkalaemia. Ectaprim’s efficacy is also officially documented to be antagonized by supplements like Folinic acid (Leucovorin). The intravenous solution formulation carries a specific prohibition against co-administration with any product containing propylene glycol.

Mechanism of Action

Sequential Inhibition of Bacterial Metabolism

Ectaprim's mechanism is driven by a simultaneous, sequential inhibition strategy targeting the essential bacterial folate biosynthesis pathway. Sulphamethoxazole inhibits the enzyme Dihydropteroate Synthase (DHPS), while Trimethoprim inhibits the subsequent enzyme, Dihydrofolate Reductase (DHFR). This two-step interference is central to its activity, resulting in a synergistic action that rapidly depletes the bacteria's supply of essential metabolic cofactors.


Arrest of Genetic Material Synthesis

The failure to produce active folate cofactors prevents the bacteria from synthesizing the essential building blocks, such as purines and thymidylate, required for DNA and protein production. This state of metabolic failure prevents the infectious agent from replicating or repairing its genetic material, triggering a bactericidal effect against susceptible microorganisms. This biological action leads to a reduction of the viable microbial population.


Mechanism Constraints

This mechanism can be physiologically constrained. Certain bacterial resistance mutations can reduce the drug's affinity for DHPS or DHFR. Furthermore, the presence of high concentrations of pre-formed folates in the infection environment (e.g., pus) can occasionally be used by the bacteria to bypass the metabolic block, locally reducing the mechanism's effectiveness.

Dosage and Administration Information

How to use Ectaprim

Ectaprim is a trade name for the combination antibiotic Co-trimoxazole, and its usage is strictly defined by guidelines to ensure appropriate administration. The medicine is approved for two primary routes: Oral (as a Tablet or Oral Suspension) and via Intravenous (IV) Infusion.


Official Administration and Dosing

The standard adult regimen for common acute infections, such as a urinary tract infection, specifies taking one Double Strength (DS) Tablet (800 mg Sulfamethoxazole / 160 mg Trimethoprim) or its equivalent twice daily (every 12 hours). Oral doses may be taken with food or drink to minimize gastrointestinal upset.

High-dose regimens, such as for the treatment of Pneumocystis jirovecii Pneumonia (PJP), require calculating the dose based on the Trimethoprim component (15 to 20 mg/kg/day), administered in three or four divided doses daily.


Procedural Requirements and Adjustments

For the intravenous form, the concentrate must be diluted prior to use and administered as a slow infusion over a period of 60 to 90 minutes; rapid injection is prohibited. The medicine is contraindicated in infants younger than 2 months of age. Dose adjustments are required for patients with impaired kidney function; those with a Creatinine Clearance (CrCl) between 15 and 30 mL/min must receive half of the standard recommended dose. If a dose is missed, it should only be taken if less than six hours overdue.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ectaprim (Co-trimoxazole)

This section provides an overview of the clinical research and study types that have been conducted to evaluate Ectaprim, reflecting the official evidence landscape. It describes what researchers explored and what has been reported, without offering any clinical advice or individual guidance.


Evidence for Use in Core Infections

Research for severe or complicated Urinary Tract Infections (UTI) was evaluated in Controlled Clinical Trials monitoring outcomes related to bacteriological clearance and symptom change in adult and pediatric populations. The findings describe patterns observed in these studies.

The combination was also studied for acute infections, including Shigellosis (bacterial diarrhea) and Acute Exacerbations of Chronic Bronchitis (AECB). These research scenarios primarily examined outcomes describing episodic changes and outcomes related to physical discomfort. Evidence quality varies across studies for these acute uses, and for applications like Acute Otitis Media (AOM), the evidence relies heavily on historical trials.


Evidence for Treatment and Prevention of PJP

The evidence for Pneumocystis Jirovecii Pneumonia (PJP) includes Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies explored two primary scenarios: treatment during active infection and prevention (prophylaxis) in immunocompromised patients.

In the prophylaxis setting, long-term Cohort Studies explored outcomes related to the incidence rate of PJP diagnosis and all-cause mortality over extended intervals. These findings contribute to the broader evidence landscape related to prevention in these high-risk settings.


Research Limitations and Gaps

Most data captures short-term symptom patterns, and research for certain subgroups, such as pregnant patients, remains insufficient. For certain non-HIV immunocompromised groups, follow-up durations were limited, meaning long-term outcomes are not fully established. Research is ongoing regarding optimal dosing, and continuous monitoring of bacterial susceptibility is necessary because the utility of any antibiotic may change over time as resistance patterns emerge.

Key Studies & References

  1. WHO Model List of Essential Medicines - 23rd list
  2. Sulfamethoxazole and Trimethoprim: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Ectaprim (FAQ)


Q: Is Ectaprim the same as other medicines I've seen advertised for similar issues?

Ectaprim is the trade name for the combination medicine Co-trimoxazole. Official product information highlights that it is distinguished by a dual-action mechanism; it uses two active ingredients, Sulphamethoxazole and Trimethoprim, to target two sequential steps in the bacterial life cycle. This combination is designed to produce a synergistic effect against susceptible infectious agents.


Q: How quickly does Ectaprim usually start working for the condition it treats?

Studies on the medicine's activity show that after an oral dose, the active ingredients typically reach their peak levels in the blood within 1 to 4 hours. However, the time it takes to observe noticeable improvement in symptoms can vary depending on the type and severity of the infection being treated.


Q: Can Ectaprim be taken with common pain relievers like ibuprofen or acetaminophen?

Official drug information does not typically list specific interactions with common pain relievers such as ibuprofen or acetaminophen. However, regulatory documents note that caution is required for co-administration with medicines that are known to affect kidney function or potassium levels in the blood.


Q: Does Ectaprim interact with birth control pills?

Regulatory interaction studies and medical consensus indicate that Ectaprim does not typically interfere with the effectiveness of common hormonal contraceptive methods, such as birth control pills, the patch, or the vaginal ring.


Q: Does Ectaprim affect my ability to drive or operate machinery?

Official regulatory listings note that some nervous system side effects are associated with the drug's use. Effects such as dizziness or unsteadiness may occur, which means that the ability to drive or operate heavy machinery may be impaired.


Q: What happens if I miss a dose of Ectaprim?

Official instructions concerning a missed oral dose state that the window for taking the dose is less than six hours overdue. Information regarding missed doses outside this time frame or for the intravenous form is defined by the original prescribing instructions.


Q: How long does Ectaprim stay in your system after the last dose?

The time it takes for the medicine to be cleared from the body is measured by its half-life. The mean serum half-lives of the two components are approximately 8 to 10 hours. While most of the medicine is cleared relatively quickly, trace amounts may be detectable for up to 24 hours after administration.


Q: Is it true that Ectaprim can make your skin more sensitive to the sun?

Yes, official warnings note that Ectaprim can increase sensitivity to sunlight (photosensitivity). Official warnings note that protective measures, such as wearing sunscreen or protective clothing, are associated with its use.


Q: Does Ectaprim interfere with vitamins or mineral supplements?

Official documents note specific interactions. For example, the medicine is antagonized by Folinic acid supplements, which may reduce its efficacy. Additionally, co-administration with potassium supplements is associated with an increased risk of hyperkalaemia (high blood potassium).


Q: What if Ectaprim doesn't seem to be working after a few days?

Regulatory patient information states that while it is common to feel better early in the course of treatment, official regulatory information states that the course of medication is intended to be completed as directed. The medicine's efficacy can sometimes be constrained by factors such as bacterial resistance, which may reduce its expected effect against the infection.


Q: Why might a doctor prescribe Ectaprim instead of another medicine?

The prescribing choice is often based on the drug's unique mechanism. The medicine employs a powerful dual blockade strategy that is highly effective against specific susceptible bacteria because it attacks two sequential stages of the folate pathway required for the bacteria's survival.


Q: Does Ectaprim need to be refrigerated or stored in a special way?

Official storage instructions specify that tablets should be kept at controlled room temperature, typically 68 F to 77 F (20 C to 25 C). The liquid oral suspension must be protected from light, and the injection solution concentrate must not be refrigerated.


Q: Do many people experience stomach issues or nausea when taking Ectaprim?

Official regulatory documents list several gastrointestinal issues as common side effects. These frequently reported effects include both nausea and diarrhoea.


Q: Are there any long-term effects associated with using Ectaprim?

Official research outlines that data for long-term outcomes remains limited for certain patient groups. However, for patients requiring prolonged therapy, regulatory guidelines state that routine monitoring of blood counts is required to be performed.


Q: Can Ectaprim affect blood sugar levels?

Official labeling notes that the drug may affect blood sugar levels. Specifically, it can increase the risk of hypoglycemia (low blood sugar), which is a particular concern for patients already taking certain other diabetes medicines.


Q: Is there a link between Ectaprim and changes in mood?

Official documents list various nervous system effects such as confusion or apathy as possible side effects. Furthermore, low blood sugar, which is a possible effect of the medicine, can also be associated with changes in mood or behavior.


Q: Is Ectaprim effective against resistant bacteria?

While resistance can reduce the drug's effectiveness, official guidance notes that susceptibility testing is required to confirm whether the specific infectious agent causing the illness is treatable by the medicine.


Q: What information is available about Ectaprim's safety profile in people with heart issues?

Official warnings note a formal contraindication against co-use with the anti-arrhythmic medicine Dofetilide. Additionally, the medicine carries a documented increased risk of hyperkalaemia (high potassium) when combined with certain blood pressure and heart-related medicines.


Q: Can I stop taking Ectaprim if I notice a rash?

Official safety documents state that the medicine is required to be discontinued at the first appearance of any skin rash or any sign that might indicate a serious adverse event.


Q: Does the efficacy of Ectaprim depend on what time of day I take it?

Official dosing guidelines focus on maintaining the correct interval between doses (e.g., every 12 hours for a twice-daily regimen). There is no official information stating that the drug's efficacy is dependent on the specific time of day the dose is administered.


Q: Can I drink coffee while taking Ectaprim?

Regulatory safety information does not list a direct drug interaction with caffeine. However, regulatory safety information notes that caution is associated with caffeine's mild diuretic effects (increased urination), as this may contribute to the risk of dehydration during treatment.

How should Ectaprim be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies establish specific conditions for storing and disposing of Ectaprim (sulfamethoxazole/trimethoprim) to ensure stability and safety.

Storage Constraints:

  • Temperature: Store the product, including tablets, at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C).
  • Protection: The oral suspension form must be protected from light. Keep containers tightly closed to guard against moisture, and the injection solution must not be refrigerated.
  • Child Safety: All forms of the medication must be kept out of the reach of children.

Disposal Instructions:

  • Unused/Expired Product: Dispose of any unused or expired Ectaprim by following established governmental drug take-back or disposal guidelines.
  • Environmental Warning: Due to its toxicity to aquatic life, disposal must avoid release into the environment, such as flushing down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ectaprim found in:

A-Z Index: